Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference
November 22, 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
November 14, 2023 16:05 ET
|
Solid Biosciences Inc.
– Planning to initiate Phase 1/2 trial in pediatric DMD Patients –– First cohort to study patients 4 to < 6 years of age –CHARLESTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences...
Solid Biosciences to Participate at Jefferies London Healthcare Conference
November 09, 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Provides Third Quarter Business Update and Financial Results
November 08, 2023 16:17 ET
|
Solid Biosciences Inc.
– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter...
Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
October 02, 2023 08:00 ET
|
Solid Biosciences Inc.
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid’s focus on both...
Solid Biosciences to Participate at Upcoming Investor Conferences
September 20, 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Participate at Upcoming Investor Conferences
September 05, 2023 08:56 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference
August 31, 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences Provides Second Quarter Business Update and Financial Results
August 14, 2023 16:17 ET
|
Solid Biosciences Inc.
– On track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Executed licensing agreement for development and...
Solid Biosciences to Participate at the Jefferies Healthcare Conference
June 01, 2023 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...